X4 Pharmaceuticals (XFOR) Expected to Announce Quarterly Earnings on Tuesday

X4 Pharmaceuticals (NASDAQ:XFOR) is expected to announce its earnings results before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $1.07 million for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

X4 Pharmaceuticals Stock Performance

Shares of NASDAQ XFOR opened at $0.31 on Friday. The company’s fifty day moving average price is $0.46 and its 200 day moving average price is $0.53. X4 Pharmaceuticals has a 1 year low of $0.26 and a 1 year high of $1.60. The company has a market capitalization of $52.41 million, a PE ratio of -3.41 and a beta of 0.39. The company has a debt-to-equity ratio of 1.26, a quick ratio of 4.80 and a current ratio of 4.89.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $1.50 price target on shares of X4 Pharmaceuticals in a report on Friday, February 7th.

Insider Buying and Selling

In related news, CFO Adam S. Mostafa sold 74,773 shares of the stock in a transaction on Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $33,647.85. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Paula Ragan sold 76,473 shares of the stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $34,412.85. Following the sale, the chief executive officer now directly owns 1,087,386 shares in the company, valued at $489,323.70. This trade represents a 6.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 202,663 shares of company stock valued at $91,198. Corporate insiders own 1.62% of the company’s stock.

Hedge Funds Weigh In On X4 Pharmaceuticals

A hedge fund recently raised its stake in X4 Pharmaceuticals stock. Bank of America Corp DE raised its stake in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 20.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 133,502 shares of the company’s stock after purchasing an additional 22,485 shares during the period. Bank of America Corp DE owned 0.08% of X4 Pharmaceuticals worth $98,000 at the end of the most recent quarter. Institutional investors and hedge funds own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.